Ovarian Cancer - Drug Pipeline Landscape, 2023

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,000	736 Pages	Global Insight Services	January, 2023	GIS17645041

Best Price Guarantee
Price	from $2,000
Length	736 Pages
Publisher	Global Insight Services
Published Date	January, 2023
SKU	GIS17645041

Ovarian Cancer - Drug Pipeline Landscape, 2023

Ovarian Cancer is a growth of abnormal cells in the ovaries or fallopian tubes and peritoneum which can multiply without any control. It is of three types based on the origination in cell types which are epithelial ovarian cancer, stromal tumor and germ cell tumor.

The exact cause of Ovarian cancer is still unclear but the risk factors include family history of ovarian/breast cancer, inherited gene mutations (BRCA1 or BRCA2) or Lynch syndrome, age, obesity, endometriosis, hormone replacement treatment, never been pregnant.

The most common symptoms of Ovarian cancer include vaginal bleeding (post menopause), abnormal vaginal discharge, bloating, pelvic and/or abdominal pain, discomfort, back pain, bowel changes (diarrhea or constipation), frequent urination, fatigue, loss of appetite.

Ovarian Cancer can be diagnosed by the doctors with a medical history and physical exam. The physical exam should include a pelvic and rectal examination. Blood tests that may be used to diagnose ovarian cancer include complete blood count, liver/kidney function tests, cancer antigen 125 levels, HCG levels, lactate dehydrogenase levels, alpha-fetoprotein, inhibin, estrogen and testosterone levels. Other diagnostic studies include biopsy and imaging tests.

The most common treatments for Ovarian cancer are surgery, chemotherapy, radiotherapy, hormonal therapy, targeted therapy, immunotherapy (biotherapy).

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Ovarian Cancer treatment such as Cediranib, Dostarlimab and Niraparib combination, Alpelisib, Rucaparib (1L), Pembrolizumab, and others. Key players involved in the development of therapies to treat ovarian cancer are AstraZeneca, GlaxoSmithKline, Novartis, Clovis Oncology Inc, Merck and others. Twenty-one drugs are under late-stage Phase III clinical trials and one-hundred twenty-seven drugs are in Phase II clinical trials, one-hundred twenty-three drugs are under Phase I and some other drugs are under Phase 0, IND/CTA filed, preclinical and discovery stages of development.

Report Highlights

Global Insight Service’s, Ovarian Cancer - Drug Pipeline Landscape, 2023 report provides an overview of the Ovarian Cancer pipeline drugs. This report covers detailed insights on Ovarian Cancer drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Ovarian Cancer pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction: 1.1 Ovarian Cancer – Pipeline Drugs, 2023 – Coverage
2. Disease Overview – Ovarian Cancer: 2.1 Causes; 2.2 Signs and Symptoms; 2.3 Diagnosis; 2.4 Disease Management
3. Ovarian Cancer – Pipeline Drugs Development – Overview: 3.1 Comparative Analysis by Stage of Development; 3.2 Number of Products under Development by Companies, 2023; 3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics: 4.1 Assessment by Target; 4.2 Assessment by Mechanism of Action; 4.3 Assessment by Molecule Type; 4.3 Assessment by Route of Administration
5. Drug Profiles: 5.1 Clinical Stage Drugs – Phase III; 5.1.1 Alpelisib; 5.1.2 Anlotinib Hydrochloride; 5.1.3 Atezolizumab; 5.1.4 Batiraxcept; 5.1.5 BD0801; 5.1.6 Cediranib; 5.1.7 Chiauranib; 5.1.8 Dostarlimab + Niraparib; 5.1.9 Letrozole; 5.1.10 Nemvaleukin Alfa; 5.1.11 Nivolumab; 5.1.12 Olvimulogene Nanivacirepvec; 5.1.13 Oregovomab; 5.1.14 Pembrolizumab; 5.1.15 Relacorilant; 5.1.16 Rucaparib (1L); 5.1.17 Senaparib; 5.1.18 Talazoparib; 5.1.19 TQB2450; 5.1.20 Upifitamab Rilsodotin; 5.1.21 Veliparib; 5.2 Clinical Stage Drugs – Phase II; 5.2.1 [225Ac]-FPI-1434; 5.2.2 [225Ac]-FPI-1966; 5.2.3 A166; 5.2.4 Abemaciclib; 5.2.5 ACR-368; 5.2.6 Afuresertib; 5.2.7 AK112; 5.2.8 AMXI-5001; 5.2.9 AMXT 1501 Dicaprate with Difluoromethylornithine; 5.2.10 Anti-ALPP CART-cells; 5.2.11 Anti-C-met Antibody; 5.2.12 ART0380; 5.2.13 ASP0739; 5.2.14 ATX-101; 5.2.15 AVB-001; 5.2.16 AVOVA-1; 5.2.17 Avutometinib; 5.2.18 AZD5305; 5.2.19 AZD8205; 5.2.20 AZD9574; 5.2.21 Balstilimab; 5.2.22 Bemarituzumab; 5.2.23 BLU-222; 5.2.24 BNT141; 5.2.25 BNT211; 5.2.26 BT5528; 5.2.27 BT8009; 5.2.28 Cabozantinib; 5.2.29 Camrelizumab; 5.2.30 CBX-12; 5.2.31 Cemiplimab; 5.2.32 Ceralasertib; 5.2.33 CM-24; 5.2.34 COM701; 5.2.35 Copanlisib; 5.2.36 CPO-100; 5.2.37 CTX-009; 5.2.38 CYH33; 5.2.39 CYT-0851; 5.2.40 Datopotamab Deruxtecan; 5.2.41 DCVAC/OvCa; 5.2.42 Defactinib; 5.2.43 E-602; 5.2.44 Elraglusib; 5.2.45 ELU001; 5.2.46 ENB003; 5.2.47 Enzalutamide; 5.2.48 EP0057; 5.2.49 Epacadostat; 5.2.50 ESG401; 5.2.51 Famitinib Malate; 5.2.52 Farletuzumab Ecteribulin; 5.2.53 Fulvestrant; 5.2.54 Galinpepimut-S; 5.2.55 Gavocabtagene Autoleucel; 5.2.56 GEN-1; 5.2.57 GEN1047; 5.2.58 Gimatecan; 5.2.59 I/ONTAK; 5.2.60 IMX-110; 5.2.61 IN10018; 5.2.62 INCB001158; 5.2.63 Ipatasertib; 5.2.64 Ipilimumab; 5.2.65 JAB-8263; 5.2.66 Lenvatinib; 5.2.67 LN-145-S1; 5.2.68 LOAd703; 5.2.69 MAK683; 5.2.70 Maveropepimut-S; 5.2.71 Mecbotamab Vedotin; 5.2.72 MK-4830; 5.2.73 MK-7684A; 5.2.74 Modi-1; 5.2.75 Nanrilkefusp alfa; 5.2.76 Navicixizumab; 5.2.77 NC410; 5.2.78 NC762; 5.2.79 NGM120; 5.2.80 NGM707; 5.2.81 Nirogacestat; 5.2.82 NP-G2-044; 5.2.83 NT-I7; 5.2.84 NTX-301; 5.2.85 NUV-868; 5.2.86 OC-001; 5.2.87 Ombipepimut-S; 5.2.88 Onapristone ER; 5.2.89 ONC-392; 5.2.90 ONCOS-102; 5.2.91 OSE2101; 5.2.92 Ozuriftamab Vedotin; 5.2.93 Palbociclib; 5.2.94 PF-06873600; 5.2.95 PF-07104091; 5.2.96 PRO1184; 5.2.97 REGN5668; 5.2.98 Regorafenib; 5.2.99 Ribociclib; 5.2.100 Rintatolimod; 5.2.101 RRx-001; 5.2.102 SC10914; 5.2.103 Seribantumab; 5.2.104 SKB264; 5.2.105 SQ3370; 5.2.106 Stenoparib; 5.2.107 T3011; 5.2.108 TAK228; 5.2.109 Tazemetostat; 5.2.110 TC-510; 5.2.111 TCR-T Cell Drug Product with Aldesleukin; 5.2.112 Tisotumab Vedotin; 5.2.113 TPIV200; 5.2.114 TQ-B3525; 5.2.115 TransCon IL-2 β/γ; 5.2.116 Trastuzumab Deruxtecan; 5.2.117 Tremelimumab; 5.2.118 TTI-622; 5.2.119 Ubamatamab; 5.2.120 Uliledlimab; 5.2.121 Vigil; 5.2.122 Vismodegib; 5.2.123 Vudalimab; 5.2.124 ZB131; 5.2.125 ZEN003694; 5.2.126 Zilovertamab Vedotin; 5.2.127 ZN-c3; 5.3 Clinical Stage Drugs – Phase I; 5.3.1 6B11-OCIK Injection; 5.3.2 AB-1015; 5.3.3 ABBV-181; 5.3.4 ABBV-368; 5.3.5 ADCT-901; 5.3.6 ADP-A2M4CD8; 5.3.7 AMG 650; 5.3.8 APG-2449; 5.3.9 ASN004; 5.3.10 ASP1948; 5.3.11 ATRC-101; 5.3.12 AVA6000; 5.3.13 AZD5363; 5.3.14 BAY2287411; 5.3.15 BCA101; 5.3.16 Belinostat; 5.3.17 Bevacizumab-ADNAB; 5.3.18 BNT115; 5.3.19 Botensilimab; 5.3.20 BP1001-A; 5.3.21 Camidanlumab Tesirine; 5.3.22 CART-TnMUC1; 5.3.23 CDX-527; 5.3.24 Cellgram-DC; 5.3.25 Cobimetinib; 5.3.26 CRX100; 5.3.27 CT-0508; 5.3.28 CUE-102; 5.3.29 DCP-001; 5.3.30 DeTIL-0255; 5.3.31 DP303c; 5.3.32 DS-6000; 5.3.33 DS-9606; 5.3.34 Dubermatinib; 5.3.35 Eganelisib; 5.3.36 ELI-002; 5.3.37 Enitociclib; 5.3.38 ETC-1922159; 5.3.39 Etrumadenant; 5.3.40 Evorpacept; 5.3.41 Follicle Stimulating Hormone Receptor T Cells; 5.3.42 Fostamatinib; 5.3.43 FT536; 5.3.44 Genetically-modified T Cells; 5.3.45 GRN-300; 5.3.46 GSK4381562; 5.3.47 GSK4428859A; 5.3.48 HuCART-meso Cells; 5.3.49 IMC002; 5.3.50 IMGN151; 5.3.51 IMP7068; 5.3.52 INCB106385; 5.3.53 INCB123667; 5.3.54 IPH5301; 5.3.55 ITIL-306; 5.3.56 JNJ-78306358; 5.3.57 KFA115; 5.3.58 Lemzoparlimab; 5.3.59 Lorigerlimab; 5.3.60 LXH254; 5.3.61 LY3475070; 5.3.62 LY3537982; 5.3.63 Mitoxantrone Hydrochloride Liposome Injection; 5.3.64 MRx0518; 5.3.65 Naptumomab Estafenatox; 5.3.66 Neratinib; 5.3.67 NGM438; 5.3.68 NGM831; 5.3.69 NI-1801; 5.3.70 NMS-03305293; 5.3.71 NX-1607; 5.3.72 OCN-201; 5.3.73 OVM-200; 5.3.74 Paclitaxel (Albumin-bound); 5.3.75 Pegilodecakin; 5.3.76 PF-06940434; 5.3.77 PF-07257876; 5.3.78 PF-07260437; 5.3.79 Pidnarulex; 5.3.80 P-MUC1C-ALLO1 CAR-T Cells; 5.3.81 PRGN-3005 UltraCAR-T Cells; 5.3.82 PY159; 5.3.83 PY314; 5.3.84 QBS10072S; 5.3.85 Radspherin; 5.3.86 REC-4881; 5.3.87 RP12146; 5.3.88 SEA-TGT; 5.3.89 Selumetinib; 5.3.90 SG001; 5.3.91 SGN-ALPV; 5.3.92 SGN-B6A; 5.3.93 SGN-B7H4V; 5.3.94 SGN-PDL1V; 5.3.95 SGN-STNV; 5.3.96 Sitravatinib; 5.3.97 SL-172154; 5.3.98 SNX281; 5.3.99 SRA515; 5.3.100 STK-012; 5.3.101 STRO-002; 5.3.102 TBI-1301; 5.3.103 Tebotelimab +/- Margetuximab; 5.3.104 TG4050; 5.3.105 TH1902; 5.3.106 TILT-123; 5.3.107 Tilvestamab; 5.3.108 Tislelizumab; 5.3.109 TORL-1-23; 5.3.110 TRK-950; 5.3.111 Unesbulin; 5.3.112 VCN-01; 5.3.113 Vic-trastuzumab Duocarmazine; 5.3.114 VMD-928; 5.3.115 Vobramitamab Duocarmazine; 5.3.116 XB002; 5.3.117 XL102; 5.3.118 XmAb22841; 5.3.119 XmAb808; 5.3.120 XMT-1660; 5.3.121 Zanidatamab; 5.3.122 Zanidatamab Zovodotin; 5.3.123 Zimberelimab; 5.4 Early Stage Drugs – Phase 0; 5.4.1 Alsevalimab; 5.4.2 Anti-mesothelin Chimeric Antigen Receptor-T Cells; 5.5 Early Stage Drugs – IND/CTA Filed; 5.5.1 KVA 12123; 5.5.2 SynKIR-110; 5.6 Early Stage Drugs – Preclinical; 5.6.1 A2B 694; 5.6.2 ACE1702; 5.6.3 ALEXIS-ISO-1; 5.6.4 AMG 794; 5.6.5 AMP 945; 5.6.6 AMT-151; 5.6.7 Anti-HER2-TAP; 5.6.8 AT 501; 5.6.9 AVB 002; 5.6.10 AVB-002; 5.6.11 BNT212; 5.6.12 BNT221 (NEO-PTC-01); 5.6.13 BP 1003 Plus Chemotherapy (Taxol, 5-fluorouracil); 5.6.14 BVX 0918A; 5.6.15 CARG 2020; 5.6.16 CD24 Modulator; 5.6.17 CE 001; 5.6.18 CE 004; 5.6.19 CT-1119; 5.6.20 CTX 2026; 5.6.21 CUSP06; 5.6.22 CX 801; 5.6.23 CX 803; 5.6.24 CX 804; 5.6.25 Dovitinib; 5.6.26 ERX 208; 5.6.27 ERX 41; 5.6.28 ExoASO STAT6; 5.6.29 EXS 617; 5.6.30 GB 7008-03; 5.6.31 GB 7008-05; 5.6.32 GDT002; 5.6.33 GMA 202; 5.6.34 GP 2250; 5.6.35 GT-001; 5.6.36 GT-00A x IL15; 5.6.37 IKS 012; 5.6.38 IOC-001; 5.6.39 ITM 52; 5.6.40 IVX037; 5.6.41 Jantibody; 5.6.42 KAND145; 5.6.43 KAND567; 5.6.44 KSQ-4279; 5.6.45 KVX-053; 5.6.46 LiPax; 5.6.47 LM 002; 5.6.48 MB1707; 5.6.49 MT-401-OTS; 5.6.50 NeoTCR P201; 5.6.51 OI-3; 5.6.52 OMTX 705; 5.6.53 ONC 206; 5.6.54 Onvansertib; 5.6.55 Ovarian Cancer Vaccine; 5.6.56 PDS 0103; 5.6.57 PH 762; 5.6.58 PT796; 5.6.59 PT895; 5.6.60 PTX V5; 5.6.61 PYTX-001; 5.6.62 PYTX-004; 5.6.63 RAD 207; 5.6.64 RAD 208; 5.6.65 RAD52; 5.6.66 ROR1 Modulator; 5.6.67 SA 401; 5.6.68 SBP-101; 5.6.69 Surufatinib; 5.6.70 TheoAd281; 5.6.71 TJ-C64B; 5.6.72 TJ-MU4B; 5.6.73 TNG 348; 5.6.74 TY 2699a; 5.6.75 Ulenistamab; 5.6.76 UP 284; 5.6.77 VIP236; 5.6.78 WT1 Modulator; 5.6.79 ZW171; 5.6.80 ZW191; 5.6.81 ZW220; 5.7 Early Stage Drugs – Discovery; 5.7.1 AWAKE LM TT; 5.7.2 Cyclin-dependent Kinase 2 (CDK2) Modulators; 5.7.3 DNA Damage Response Modulators; 5.7.4 ERXC 102; 5.7.5 ET-201; 5.7.6 IDC 001; 5.7.7 IDC 002; 5.7.8 IDC 004; 5.7.9 IDC 008; 5.7.10 IDC 009; 5.7.11 IMC005; 5.7.12 LEAD 472; 5.7.13 LR 06B; 5.7.14 Polypharmacology B Modulators; 5.7.15 PT790; 5.7.16 PYTX 002; 5.7.17 PYTX 003; 5.7.18 UBR5 Inhibitors; 5.7.19 Undisclosed; 5.7.20 Undisclosed HRD-Negative Ovarian Cancer Target Gamma Drug; 5.7.21 Undisclosed Small Molecule; 5.7.22 WP1244
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved: 9.1 4D pharma plc; 9.2 A*STAR Research Entities; 9.3 A2 Biotherapeutics; 9.4 AbbVie; 9.5 Abclon; 9.6 Acepodia Biotech, Inc.; 9.7 Acrivon Therapeutics; 9.8 Acrotech Biopharma; 9.9 Actuate Therapeutics; 9.10 Adaptimmune; 9.11 ADC Therapeutics S.A.; 9.12 Advenchen Laboratories, LLC; 9.13 Agenus Inc.; 9.14 AIM ImmunoTech Inc; 9.15 Aivita Biomedical, Inc.; 9.16 Akeso; 9.17 Alaunos Therapeutics; 9.18 Alkermes, Inc; 9.19 Allarity Therapeutics; 9.20 ALX Oncology; 9.21 Amgen; 9.22 Aminex Therapeutics, Inc.; 9.23 Amplia Therapeutics; 9.24 Anixa Biosciences, Inc.; 9.25 Apim Therapeutics; 9.26 Aravive, Inc; 9.27 Arcus Biosciences, Inc; 9.28 Arsenal Biosciences, Inc.; 9.29 Artios Pharma Ltd; 9.30 Asana BioSciences; 9.31 Ascendis Pharma A/S; 9.32 Ascentage Pharma Group Inc; 9.33 Astellas Pharma Inc; 9.34 AstraZeneca; 9.35 AtlasMedx, Incorporated; 9.36 Atreca, Inc.; 9.37 Avacta Life Sciences Ltd; 9.38 Avenge Bio, Inc; 9.39 Bayer; 9.40 BeiGene; 9.41 Beijing Weixiao Biotechnology Development Limited; 9.42 BerGenBio ASA; 9.43 Bicara Therapeutics; 9.44 BicycleTx Limited; 9.45 BioAtla, Inc.; 9.46 BioEclipse Therapeutics; 9.47 BioNTech SE; 9.48 Bio-Path Holdings, Inc.; 9.49 BioVaxys; 9.50 Blueprint Medicines Corporation; 9.51 Bridge Medicines; 9.52 BridGene Biosciences; 9.53 Bristol Myers Squibb; 9.54 Byondis B.V.; 9.55 CanariaBio Inc; 9.56 Cardiff Oncology; 9.57 Carisma Therapeutics Inc; 9.58 CaroGen; 9.59 Cartexell; 9.60 Celldex Therapeutics; 9.61 Cello Therapeutics; 9.62 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; 9.63 Chimerix; 9.64 Chipscreen Biosciences, Ltd.; 9.65 Citius Pharmaceuticals, Inc; 9.66 Clovis Oncology, Inc; 9.67 CNS Pharmaceuticals; 9.68 Codiak BioSciences; 9.69 Compass Therapeutics; 9.70 Compugen Ltd; 9.71 Context Therapeutics Inc.; 9.72 Corcept Therapeutics; 9.73 CSPC Pharmaceutical Group Limited; 9.74 Cue Biopharma; 9.75 Cybrexa Therapeutics; 9.76 Cyteir Therapeutics, Inc.; 9.77 Daiichi Sankyo, Inc.; 9.78 DeepCure; 9.79 Eikonoklastes Therapeutics; 9.80 Eisai Inc.; 9.81 Elevation Oncology; 9.82 Eli Lilly and Company; 9.83 Elicio Therapeutics; 9.84 Ellipses Pharma; 9.85 Elucida Oncology; 9.86 ENB Therapeutics, Inc; 9.87 EnduRx Pharmaceuticals; 9.88 EpicentRx, Inc.; 9.89 EtiraRx; 9.90 Eureka Therapeutics; 9.91 Exelixis; 9.92 Exscientia; 9.93 Fate Therapeutics; 9.94 Five Prime Therapeutics, Inc.; 9.95 Fusion Pharmaceuticals Inc.; 9.96 Gadeta B.V.; 9.97 Genelux Corporation; 9.98 Genentech, Inc; 9.99 Genmab; 9.100 GlaxoSmithKline; 9.101 Glycotope GmbH; 9.102 Gmax Biopharm; 9.103 Gradalis, Inc.; 9.104 Greenfire Bio; 9.105 Haihe Biopharma Co., Ltd.; 9.106 Handok Pharmaceuticals, Inc; 9.107 H-CYTE; 9.108 Helixmith; 9.109 Hoffmann-La Roche; 9.110 Hrain Biotechnology Co., Ltd.; 9.111 Hutchmed; 9.112 Iksuda Therapeutics; 9.113 I-Mab Biopharma Co. Ltd.; 9.114 Immix Biopharma, Inc.; 9.115 ImmunoGen, Inc.; 9.116 ImmunoVaccine Technologies, Inc. (IMV Inc.); 9.117 ImmVira Pharma Co. Ltd; 9.118 ImmVirx Pty Ltd; 9.119 Impact Therapeutics, Inc; 9.120 Imunon; 9.121 Imvax; 9.122 Incyte Corporation; 9.123 Infinity Pharmaceuticals, Inc.; 9.124 Innate Pharma; 9.125 Instil Bio; 9.126 InxMed (Shanghai) Co., Ltd.; 9.127 Iovance Biotherapeutics, Inc; 9.128 Ipsen; 9.129 ITM Isotope Technologies Munich SE; 9.130 Jacobio Pharmaceuticals Co., Ltd.; 9.131 Janssen Research & Development, LLC; 9.132 Jiangsu HengRui Medicine Co., Ltd.; 9.133 Jiangsu Simcere Pharmaceutical Co., Ltd.; 9.134 Jiangxi Qingfeng Pharmaceutical Co. Ltd.; 9.135 Kancera AB; 9.136 KeViRx; 9.137 Kineta, Inc; 9.138 Kiromic; 9.139 Klus Pharma Inc.; 9.140 KSQ Therapeutics; 9.141 Laekna Limited; 9.142 Laevoroc Oncology; 9.143 LaNova Medicines Limited; 9.144 LeadArtis; 9.145 Lee’s Pharmaceutical Limited; 9.146 Light Chain Bioscience – Novimmune SA; 9.147 LIPAC Oncology; 9.148 Loki Therapeutics; 9.149 Lokon Pharma AB; 9.150 MacroGenics; 9.151 Mainline Biosciences, Inc.; 9.152 Marker Therapeutics, Inc.; 9.153 Mendus; 9.154 Merck; 9.155 Mersana Therapeutics; 9.156 Monte Rosa Therapeutics; 9.157 Multitude Therapeutics Inc; 9.158 NeoImmuneTech; 9.159 NeoTX Therapeutics Ltd; 9.160 Nerviano Medical Sciences; 9.161 NextCure, Inc.; 9.162 NGM Biopharmaceuticals, Inc; 9.163 Novartis; 9.164 Novita Pharmaceuticals, Inc.; 9.165 Nurix Therapeutics, Inc.; 9.166 Nuvation Bio Inc.; 9.167 Ocellaris Pharma, Inc.; 9.168 OncoC4, Inc; 9.169 Oncoinvent AS; 9.170 Oncomatryx; 9.171 Onconic Therapeutics Inc.; 9.172 OnCusp Therapeutics; 9.173 OncXerna Theraputics, Inc.; 9.174 OSE Immunotherapeutics; 9.175 Oxford Vacmedix UK Ltd.; 9.176 PACT Pharma; 9.177 Palleon Pharmaceuticals, Inc.; 9.178 Panavance Therapeutics; 9.179 Panbela Therapeutics; 9.180 Papyrus Therapeutics; 9.181 PDS Biotechnology Corporation; 9.182 Pfizer; 9.183 Phanes Therapeutics; 9.184 Pharmicell Co., Ltd.; 9.185 Pheast Therapeutics; 9.186 Phio Pharmaceuticals; 9.187 pHion Therapeutics; 9.188 Pionyr Immunotherapeutics Inc; 9.189 Poseida Therapeutics, Inc.; 9.190 Precigen, Inc; 9.191 Prestige BioPharma; 9.192 ProfoundBio US Co.; 9.193 PTC Therapeutics; 9.194 Puma Biotechnology, Inc; 9.195 Purple Biotech Ltd; 9.196 Quadriga Biosciences, Inc; 9.197 Radiopharm Theranostics; 9.198 Rain Therapeutics Inc.; 9.199 Recursion Pharmaceuticals; 9.200 Regeneron Pharmaceuticals; 9.201 Rhizen Pharmaceuticals SA; 9.202 Rigel Pharmaceuticals; 9.203 Scancell Ltd; 9.204 Seagen Inc; 9.205 Sellas Life Sciences Group; 9.206 Senhwa Biosciences, Inc.; 9.207 Shanghai Escugen Biotechnology Co., Ltd; 9.208 Shanghai Genechem; 9.209 Shasqi, Inc.; 9.210 Shattuck Labs, Inc.; 9.211 Shenzhen BinDeBio Ltd; 9.212 Sorrento Therapeutics, Inc.; 9.213 SOTIO Biotech AG; 9.214 SpringWorks Therapeutics, Inc.; 9.215 Stingthera, Inc; 9.216 Sumitomo Pharma Oncology, Inc.; 9.217 Sutro Biopharma, Inc.; 9.218 Suzhou Immunofoco Biotechnology Co., Ltd; 9.219 Synergys Biotherapeutics; 9.220 Synthekine; 9.221 Takara Bio Inc.; 9.222 Takeda; 9.223 Tango Therapeutics; 9.224 Targovax ASA; 9.225 TCR2 Therapeutics; 9.226 TCRCure Biopharma Ltd.; 9.227 Theolytics; 9.228 Theratechnologies; 9.229 Theriva Biologics; 9.230 TILT Biotherapeutics Ltd.; 9.231 Tmunity Therapeutics; 9.232 Toray Industries, Inc; 9.233 TORL Biotherapeutics, LLC; 9.234 Transgene; 9.235 TYK Medicine; 9.236 Up Therapeutics; 9.237 Verastem, Inc; 9.238 Verismo Therapeutics; 9.239 Vincerx Pharma, Inc.; 9.240 VM Oncology, LLC; 9.241 Wuhan Si’an Medical Technology Co. Ltd.; 9.242 Xencor, Inc; 9.243 Xennials Therapeutics Australia Pty Ltd; 9.244 Zenith Epigenetics; 9.245 Zentalis Pharmaceuticals; 9.246 ZielBio, Inc.; 9.247 Zymeworks Inc.
10. Dormant Drugs: 10.1 Inactive Drugs; 10.2 Discontinued Drugs
11. Appendix: List of Tables; Table 1.1 Number of Products Under Development for Ovarian Cancer; Table 1.2 Number of Products under Development by Companies; Table 1.3 Products under Development by Companies; Table 1.4 Products by Targets; Table 1.5 Products by Mechanism of Action; Table 1.6 Products by Molecule Type; Table 1.7 Products by Route of Administration; Table 2.1 Clinical Trial Details – Alpelisib/Novartis; Table 2.2 Clinical Trial Details – Anlotinib Hydrochloride/Advenchen Laboratories, LLC; Table 2.3 Clinical Trial Details – Atezolizumab/Hoffmann-La Roche; Table 2.4 Clinical Trial Details – Batiraxcept/Aravive, Inc; Table 2.5 Clinical Trial Details – BD0801/Jiangsu Simcere Pharmaceutical Co., Ltd.; Table 2.6 Clinical Trial Details – Cediranib/AstraZeneca; Table 2.7 Clinical Trial Details – Chiauranib/Chipscreen Biosciences, Ltd.; Table 2.8 Clinical Trial Details – Dostarlimab + Niraparib/GlaxoSmithKline; Table 2.9 Clinical Trial Details – Letrozole/Novartis; Table 2.10 Clinical Trial Details – Nemvaleukin Alfa/Alkermes, Inc; Table 2.11 Clinical Trial Details – Nivolumab/Bristol-Myers Squibb; Table 2.12 Clinical Trial Details – Olvimulogene Nanivacirepvec/Genelux Corporation; Table 2.13 Clinical Trial Details – Oregovomab/CanariaBio Inc; Table 2.14 Clinical Trial Details – Pembrolizumab/Merck; Table 2.15 Clinical Trial Details – Relacorilant/Corcept Therapeutics; Table 2.16 Clinical Trial Details – Rucaparib (1L)/Clovis Oncology, Inc; Table 2.17 Clinical Trial Details – Senaparib/Impact Therapeutics, Inc.; Table 2.18 Clinical Trial Details – Talazoparib/Pfizer; Table 2.19 Clinical Trial Details – TQB2450/Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Table 2.20 Clinical Trial Details – Upifitamab Rilsodotin/Mersana Therapeutics; Table 2.21 Clinical Trial Details – Veliparib/AbbVie; Table 2.22 Clinical Trial Details – [225Ac]-FPI-1434/Fusion Pharmaceuticals Inc.; Table 2.23 Clinical Trial Details – [225Ac]-FPI-1966/Fusion Pharmaceuticals Inc.; Table 2.24 Clinical Trial Details – A166/Klus Pharma Inc.; Table 2.25 Clinical Trial Details – Abemaciclib/Eli Lilly and Company; Table 2.26 Clinical Trial Details – ACR-368/Acrivon Therapeutics; Table 2.27 Clinical Trial Details – Afuresertib/Laekna Limited; Table 2.28 Clinical Trial Details – AK112/Akeso; Table 2.29 Clinical Trial Details – AMXI-5001/AtlasMedx, Incorporated; Table 2.30 Clinical Trial Details – AMXT 1501 Dicaprate with Difluoromethylornithine/Aminex Therapeutics, Inc.; Table 2.31 Clinical Trial Details – Anti-ALPP CART-cells/TCRCure Biopharma Ltd.; Table 2.32 Clinical Trial Details – Anti-C-met Antibody/Shenzhen BinDeBio Ltd; Table 2.33 Clinical Trial Details – ART0380/Artios Pharma Ltd; Table 2.34 Clinical Trial Details – ASP0739/Astellas Pharma Inc; Table 2.35 Clinical Trial Details – ATX-101/Apim Therapeutics; Table 2.36 Clinical Trial Details – AVB-001/Avenge Bio, Inc; Table 2.37 Clinical Trial Details – AVOVA-1/Aivita Biomedical, Inc.; Table 2.38 Clinical Trial Details – Avutometinib/Verastem, Inc; Table 2.39 Clinical Trial Details – AZD5305/AstraZeneca; Table 2.40 Clinical Trial Details – AZD8205/AstraZeneca; Table 2.41 Clinical Trial Details – AZD9574/AstraZeneca; Table 2.42 Clinical Trial Details – Balstilimab/Agenus Inc.; Table 2.43 Clinical Trial Details – Bemarituzumab/Amgen; Table 2.44 Clinical Trial Details – BLU-222/Blueprint Medicines Corporation; Table 2.45 Clinical Trial Details – BNT141/BioNTech SE; Table 2.46 Clinical Trial Details – BNT211/BioNTech SE; Table 2.47 Clinical Trial Details – BT5528/BicycleTx Limited; Table 2.48 Clinical Trial Details – BT8009/BicycleTx Limited; Table 2.49 Clinical Trial Details – Cabozantinib/Exelixis; Table 2.50 Clinical Trial Details – Camrelizumab/Jiangsu HengRui Medicine Co., Ltd.; Table 2.51 Clinical Trial Details – CBX-12/Cybrexa Therapeutics; Table 2.52 Clinical Trial Details – Cemiplimab/Regeneron Pharmaceuticals; Table 2.53 Clinical Trial Details – Ceralasertib/AstraZeneca; Table 2.54 Clinical Trial Details – CM-24/Purple Biotech Ltd; Table 2.55 Clinical Trial Details – COM701/Compugen Ltd; Table 2.56 Clinical Trial Details – Copanlisib/Bayer; Table 2.57 Clinical Trial Details – CPO-100/CSPC Pharmaceutical Group Limited; Table 2.58 Clinical Trial Details – CTX-009/Handok Pharmaceuticals, Inc; Table 2.59 Clinical Trial Details – CYH33/Haihe Biopharma Co., Ltd.; Table 2.60 Clinical Trial Details – CYT-0851/Cyteir Therapeutics, Inc.; Table 2.61 Clinical Trial Details – Datopotamab Deruxtecan/AstraZeneca; Table 2.62 Clinical Trial Details – DCVAC/OvCa/SOTIO a.s.; Table 2.63 Clinical Trial Details – Defactinib/Verastem, Inc; Table 2.64 Clinical Trial Details – E-602/Palleon Pharmaceuticals, Inc.; Table 2.65 Clinical Trial Details – Elraglusib/Actuate Therapeutics; Table 2.66 Clinical Trial Details – ELU001/Elucida Oncology; Table 2.67 Clinical Trial Details – ENB003/ENB Therapeutics, Inc; Table 2.68 Clinical Trial Details – Enzalutamide/Pfizer; Table 2.69 Clinical Trial Details – EP0057/Ellipses Pharma; Table 2.70 Clinical Trial Details – Epacadostat/Incyte Corporation; Table 2.71 Clinical Trial Details – ESG401/Shanghai Escugen Biotechnology Co., Ltd; Table 2.72 Clinical Trial Details – Famitinib Malate/Jiangsu HengRui Medicine Co., Ltd.; Table 2.73 Clinical Trial Details – Farletuzumab Ecteribulin/Eisai Inc.; Table 2.74 Clinical Trial Details – Fulvestrant/AstraZeneca; Table 2.75 Clinical Trial Details – Galinpepimut-S/Sellas Life Sciences Group; Table 2.76 Clinical Trial Details – Gavocabtagene Autoleucel/TCR2 Therapeutics; Table 2.77 Clinical Trial Details – GEN-1/Imunon; Table 2.78 Clinical Trial Details – GEN1047/Genmab; Table 2.79 Clinical Trial Details – Gimatecan/Lee’s Pharmaceutical Limited; Table 2.80 Clinical Trial Details – I/ONTAK/Citius Pharmaceuticals, Inc; Table 2.81 Clinical Trial Details – IMX-110/Immix Biopharma, Inc.; Table 2.82 Clinical Trial Details – IN10018/InxMed (Shanghai) Co., Ltd.; Table 2.83 Clinical Trial Details – INCB001158/Incyte Corporation; Table 2.84 Clinical Trial Details – Ipatasertib/Hoffmann-La Roche; Table 2.85 Clinical Trial Details – Ipilimumab/Bristol-Myers Squibb; Table 2.86 Clinical Trial Details – JAB-8263/Jacobio Pharmaceuticals Co., Ltd.; Table 2.87 Clinical Trial Details – Lenvatinib/Eisai Inc.; Table 2.88 Clinical Trial Details – LN-145-S1/Iovance Biotherapeutics, Inc; Table 2.89 Clinical Trial Details – LOAd703/Lokon Pharma AB; Table 2.90 Clinical Trial Details – MAK683/Novartis; Table 2.91 Clinical Trial Details – Maveropepimut-S/ImmunoVaccine Technologies, Inc. (IMV Inc.); Table 2.92 Clinical Trial Details – Mecbotamab Vedotin/BioAtla, Inc.; Table 2.93 Clinical Trial Details – MK-4830/Merck; Table 2.94 Clinical Trial Details – MK-7684A/Merck; Table 2.95 Clinical Trial Details – Modi-1/Scancell Ltd; Table 2.96 Clinical Trial Details – Nanrilkefusp alfa/SOTIO Biotech AG; Table 2.97 Clinical Trial Details – Navicixizumab/OncXerna Theraputics, Inc.; Table 2.98 Clinical Trial Details – NC410/NextCure, Inc.; Table 2.99 Clinical Trial Details – NC762/NextCure, Inc.; Table 2.100 Clinical Trial Details – NGM120/NGM Biopharmaceuticals, Inc; Table 2.101 Clinical Trial Details – NGM707/NGM Biopharmaceuticals, Inc; Table 2.102 Clinical Trial Details – Nirogacestat/SpringWorks Therapeutics, Inc.; Table 2.103 Clinical Trial Details – NP-G2-044/Novita Pharmaceuticals, Inc.; Table 2.104 Clinical Trial Details – NT-I7/NeoImmuneTech; Table 2.105 Clinical Trial Details – NTX-301/Xennials Therapeutics Australia Pty Ltd; Table 2.106 Clinical Trial Details – NUV-868/Nuvation Bio Inc.; Table 2.107 Clinical Trial Details – OC-001/Ocellaris Pharma, Inc.; Table 2.108 Clinical Trial Details – Ombipepimut-S/Sumitomo Pharma Oncology, Inc.; Table 2.109 Clinical Trial Details – Onapristone ER/Context Therapeutics Inc.; Table 2.110 Clinical Trial Details – ONC-392/OncoC4, Inc; Table 2.111 Clinical Trial Details – ONCOS-102/Targovax ASA; Table 2.112 Clinical Trial Details – OSE2101/OSE Immunotherapeutics; Table 2.113 Clinical Trial Details – Ozuriftamab Vedotin/BioAtla, Inc.; Table 2.114 Clinical Trial Details – Palbociclib/Pfizer; Table 2.115 Clinical Trial Details – PF-06873600/Pfizer; Table 2.116 Clinical Trial Details – PF-07104091/Pfizer; Table 2.117 Clinical Trial Details – PRO1184/ProfoundBio US Co.; Table 2.118 Clinical Trial Details – REGN5668 /Regeneron Pharmaceuticals; Table 2.119 Clinical Trial Details – Regorafenib/Bayer; Table 2.120 Clinical Trial Details – Ribociclib/Novartis; Table 2.121 Clinical Trial Details – Rintatolimod/AIM ImmunoTech Inc; Table 2.122 Clinical Trial Details – RRx-001/EpicentRx, Inc.; Table 2.123 Clinical Trial Details – SC10914/Jiangxi Qingfeng Pharmaceutical Co. Ltd.; Table 2.124 Clinical Trial Details – Seribantumab/Elevation Oncology; Table 2.125 Clinical Trial Details – SKB264/Klus Pharma Inc.; Table 2.126 Clinical Trial Details – SQ3370/Shasqi, Inc.; Table 2.127 Clinical Trial Details – Stenoparib/Allarity Therapeutics; Table 2.128 Clinical Trial Details – T3011/ImmVira Pharma Co. Ltd; Table 2.129 Clinical Trial Details – TAK228/Takeda; Table 2.130 Clinical Trial Details – Tazemetostat/Ipsen; Table 2.131 Clinical Trial Details – TC-510/TCR2 Therapeutics; Table 2.132 Clinical Trial Details – TCR-T Cell Drug Product with Aldesleukin/Alaunos Therapeutics; Table 2.133 Clinical Trial Details – Tisotumab Vedotin/Seagen Inc; Table 2.134 Clinical Trial Details – TPIV200/Marker Therapeutics, Inc.; Table 2.135 Clinical Trial Details – TQ-B3525/Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Table 2.136 Clinical Trial Details – TransCon IL-2 β/γ/Ascendis Pharma A/S; Table 2.137 Clinical Trial Details – Trastuzumab Deruxtecan/AstraZeneca; Table 2.138 Clinical Trial Details – Tremelimumab/AstraZeneca; Table 2.139 Clinical Trial Details – TTI-622/Pfizer; Table 2.140 Clinical Trial Details – Ubamatamab/Regeneron Pharmaceuticals; Table 2.141 Clinical Trial Details – Uliledlimab/I-Mab Biopharma Co. Ltd.; Table 2.142 Clinical Trial Details – Vigil/Gradalis, Inc.; Table 2.143 Clinical Trial Details – Vismodegib/Genentech, Inc; Table 2.144 Clinical Trial Details – Vudalimab/Xencor, Inc; Table 2.145 Clinical Trial Details – ZB131/ZielBio, Inc.; Table 2.146 Clinical Trial Details – ZEN003694/Zenith Epigenetics; Table 2.147 Clinical Trial Details – Zilovertamab Vedotin/Merck; Table 2.148 Clinical Trial Details – ZN-c3/Zentalis Pharmaceuticals; Table 2.149 Clinical Trial Details – 6B11-OCIK Injection/Beijing Weixiao Biotechnology Development Limited; Table 2.150 Clinical Trial Details – AB-1015/Arsenal Biosciences, Inc.; Table 2.151 Clinical Trial Details – ABBV-181/AbbVie; Table 2.152 Clinical Trial Details – ABBV-368/AbbVie; Table 2.153 Clinical Trial Details – ADCT-901/ADC Therapeutics S.A.; Table 2.154 Clinical Trial Details – ADP-A2M4CD8/Adaptimmune; Table 2.155 Clinical Trial Details – AMG 650/Amgen; Table 2.156 Clinical Trial Details – APG-2449/Ascentage Pharma Group Inc; Table 2.157 Clinical Trial Details – ASN004/Asana BioSciences; Table 2.158 Clinical Trial Details – ASP1948/Astellas Pharma Inc; Table 2.159 Clinical Trial Details – ATRC-101/Atreca, Inc.; Table 2.160 Clinical Trial Details – AVA6000/Avacta Life Sciences Ltd; Table 2.161 Clinical Trial Details – AZD5363/AstraZeneca; Table 2.162 Clinical Trial Details – BAY2287411/Bayer; Table 2.163 Clinical Trial Details – BCA101/Bicara Therapeutics; Table 2.164 Clinical Trial Details – Belinostat/Acrotech Biopharma; Table 2.165 Clinical Trial Details – Bevacizumab-ADNAB/Sorrento Therapeutics, Inc.; Table 2.166 Clinical Trial Details – BNT115/BioNTech SE; Table 2.167 Clinical Trial Details – Botensilimab/Agenus Inc.; Table 2.168 Clinical Trial Details – BP1001-A/Bio-Path Holdings, Inc.; Table 2.169 Clinical Trial Details – Camidanlumab Tesirine/ADC Therapeutics S.A.; Table 2.170 Clinical Trial Details – CART-TnMUC1/Tmunity Therapeutics